Indegene Limited , a prominent player in the Indian healthcare technology sector, has announced a significant board development. The company's Board of Directors approved the reappointment of Mr. Neeraj Bharadwaj as Non-Executive Independent Director for a five-year term on December 19, 2025, marking his return to the board in a new capacity.

Board Appointment Details

The board approval came based on the recommendation of the Nomination and Remuneration Committee. The appointment details are outlined below:

Director Profile and Qualifications

Mr. Bharadwaj brings substantial academic credentials and professional experience to the board. He holds a Bachelor of Science in Economics with a specialization in Finance from the University of Pennsylvania, Philadelphia, and an MBA in Management from Harvard University, Cambridge, Massachusetts.

His professional expertise spans multiple areas:

Regulatory Compliance and Governance

Indegene Limited has ensured full compliance with regulatory requirements for this appointment. The company confirmed that Mr. Bharadwaj is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority, as required under NSE and BSE circulars.

The disclosure has been made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has also confirmed that Mr. Bharadwaj is not related to any existing Director of the company.

Additional Board Matters

During the same board meeting, the directors also approved allotments under the company's ESOP Plan 2020 and RSU Plan 2020, demonstrating continued focus on employee incentive programs.

Srishti Ramesh Kaushik, Company Secretary and Compliance Officer of Indegene Limited, confirmed that all relevant information has been made available on the company's official website at https://www.indegene.com/ .

This reappointment reflects the company's confidence in Mr. Bharadwaj's expertise and his potential contribution to Indegene's strategic direction in the evolving healthcare technology sector.

Indegene Limited , a global technology-led healthcare solutions provider, has announced a strategic move to strengthen its European presence through the acquisition of Cake Group, a healthcare marketing and communications agency operating in the DACH region (Germany, Austria, and Switzerland).

Acquisition Details

Indegene's wholly-owned subsidiary, Indegene Ireland Limited, has signed a Share Purchase Agreement to acquire 100% equity shares in Cake Group for a consideration not exceeding EUR 8.50 million, subject to working capital and net debt adjustments. The transaction is structured as an all-cash deal with deferred performance and milestone-based considerations.

About Cake Group

Cake Group is a specialized healthcare marketing and communications agency headquartered in Vienna, Austria. The company offers a range of services including brand strategy, creative campaign development, and digital marketing solutions. With approximately 25 employees across the DACH region, Cake Group has demonstrated consistent revenue performance over the past three years:

Strategic Implications

This acquisition aligns with Indegene's strategy to expand its European footprint and enhance its capabilities in healthcare communications. By integrating Cake Group's expertise, Indegene aims to strengthen its service offerings to life sciences clients in the DACH region.

Transaction Timeline and Regulatory Approvals

The acquisition is expected to be completed in January 2026, subject to clearance under the Austrian Investment Control Act (InvKG). This regulatory approval is a crucial step in finalizing the transaction.

Market Impact

For Indegene, this acquisition represents a significant step in its European expansion strategy. It not only broadens the company's geographical presence but also adds specialized healthcare marketing capabilities to its portfolio. The move is likely to enhance Indegene's competitive position in the European healthcare solutions market.

As the healthcare sector continues to evolve, particularly in terms of digital marketing and communications, this acquisition positions Indegene to better serve the needs of pharmaceutical and life sciences companies in the DACH region.